Longeveron Inc. (LGVN)
| Market Cap | 21.11M -5.3% |
| Revenue (ttm) | 1.22M -45.3% |
| Net Income | -22.43M |
| EPS | -1.12 |
| Shares Out | 29.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 818,251 |
| Open | 0.7229 |
| Previous Close | 0.7065 |
| Day's Range | 0.7000 - 0.7499 |
| 52-Week Range | 0.4750 - 1.8000 |
| Beta | -0.32 |
| Analysts | Buy |
| Price Target | 7.15 (+891.54%) |
| Earnings Date | May 13, 2026 |
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated... [Read more]
Financial Performance
In 2025, Longeveron's revenue was $1.20 million, a decrease of -49.87% compared to the previous year's $2.39 million. Losses were -$22.70 million, -7.79% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for LGVN stock is "Buy." The 12-month stock price target is $7.15, which is an increase of 891.54% from the latest price.
News
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relate...
Longeveron Proxy statement: Proxy filing
Longeveron filed a proxy statement on May 20, 2026, providing details for shareholder voting and corporate governance matters.
Longeveron Proxy statement: Proxy filing
Longeveron filed a proxy statement on May 20, 2026, providing details for shareholder voting and corporate governance matters.
Longeveron reports Q1 EPS (19c) vs. (34c) last year
Reports Q1 revenue $398,000, consensus $323,000. “Earlier this year, we initiated a strategic repositioning of Longeveron (LGVN) designed to maximize shareholder value while maintaining disciplined ca...
Longeveron Earnings Call Transcript: Q1 2026
Q1 2026 saw stable revenue, reduced expenses, and a narrowed net loss, with cash runway into Q4 2026. Key focus is on the ELPIS II HLHS trial, with top-line data expected in August and immediate FDA engagement planned. Strategic repositioning and new investments support long-term growth.
Longeveron Quarterly report: Q1 2026
Longeveron has published its Q1 2026 quarterly earnings report on May 13, 2026.
Longeveron Earnings release: Q1 2026
Longeveron released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric diseas...
Longeveron Slides: Investor presentation
Longeveron has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Longeveron reports DMC approval for laromestrocel study to continue as designed
Longeveron (LGVN) announced that the independent data monitoring committee, or DMC, has completed its final prespecified data review for the ongoing, fully enrolled, Phase 2b clinical trial evaluating...
Longeveron downgraded to Hold from Buy at Maxim
Maxim downgraded Longeveron (LGVN) to Hold from Buy.
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication DMC performed a risk-benefit assessment...
Longeveron provides update on laromestrocel development after Type C meeting
Longeveron (LGVN) announced that a constructive Type C meeting with the FDA was held in late March, with the FDA providing their meeting summary in late April, to discuss the…
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic agin...
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relate...
Longeveron Proxy statement: Proxy filing
Longeveron filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
Longeveron Slides: Investor presentation
Longeveron has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.
Longeveron price target lowered to $8 from $10 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Longeveron (LGVN) to $8 from $10 and keeps a Buy rating on the shares. The firm cites equity dilution for the target…
Longeveron files to sell 30.87M shares of Class A common stock for holders
16:04 EDT Longeveron (LGVN) files to sell 30.87M shares of Class A common stock for holders
Longeveron Registration statement: Registration filing
Longeveron filed a registration statement on April 10, 2026, providing details about a securities offering with the SEC.
Longeveron granted Chinese patent for potency assay methods
Longeveron (LGVN) announced that the China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells derived from bon...
Longeveron granted Chinese patent for potency assay methods
Longeveron (LGVN) announced that the China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells derived from bon...
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells (MSCs).
Longeveron Slides: Investor presentation
Longeveron has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
Longeveron price target lowered to $2 from $3 at Roth Capital
Roth Capital lowered the firm’s price target on Longeveron (LGVN) to $2 from $3 but keeps a Buy rating on the shares. The firm continues to expect top-line data from…